PNP Pharmaceuticals Inc.

6 records, newest first. Each line links to the FDA page it came from.

Refusal charges, in plain English

• UNAPPROVED3 refused lines

  Unapproved new drug

  The product appeared to be a new drug within the meaning of section 201(p) of the FD&C Act without an approved New Drug Application. FDA can apply this charge to a food or supplement whose labeling presents it for drug uses.

• INCONSPICU1 refused line

  Required information not conspicuous

  Information required on the label appeared not to be placed prominently or conspicuously enough to be read and understood by an ordinary consumer.

Questions about PNP Pharmaceuticals Inc.

Is PNP Pharmaceuticals Inc. on an FDA import alert?

Yes. As of October 26, 2026, PNP Pharmaceuticals Inc. is on the red list of FDA Import Alert 54-16, “Foods/supplements with active pharmaceutical ingredient”, for u-dream lite herbal blend; FDA published the listing on May 26, 2020.

Has FDA refused shipments from PNP Pharmaceuticals Inc.?

Yes. FDA refused 4 shipment lines from PNP Pharmaceuticals Inc. between December 19, 2017 and October 8, 2020. The most recent, on October 8, 2020, was vitamin, mineral, proteins and unconventional dietary specialities for humans and animals, n.e.c., charged as UNAPPROVED (unapproved new drug).

Why did FDA refuse PNP Pharmaceuticals Inc.'s shipments?

The most frequent charges are UNAPPROVED (unapproved new drug, 3 lines) and INCONSPICU (required information not conspicuous, 1 line).

When was PNP Pharmaceuticals Inc. last inspected by FDA?

FDA's most recent inspection of PNP Pharmaceuticals Inc. with a final classification is dated January 20, 2020 and was classified NAI (No Action Indicated).

What is PNP Pharmaceuticals Inc.'s FEI number?

PNP Pharmaceuticals Inc.'s FDA Establishment Identifier (FEI) is 3003602826.

Can shipments from PNP Pharmaceuticals Inc. still enter the U.S.?

Shipments of u-dream lite herbal blend from PNP Pharmaceuticals Inc. can be detained without physical examination under Import Alert 54-16; FDA releases them only if evidence shows they do not have the listed violation. Importers must consider this listing in their FSVP evaluation (21 CFR 1.505).